

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 421  
(A-24)

Introduced by: American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, Society of American Gastrointestinal and Endoscopic Surgeons

Subject: Annual Conference on the State of Obesity and its Impact on Disease in America (SODA)

Referred to: Reference Committee D

---

1 Whereas, the American Medical Association (AMA) recognizes the critical importance of  
2 addressing the impact of obesity on various chronic diseases, including hypertension,  
3 cardiovascular disease, type 2 diabetes, and metabolic dysfunction-associated hepatitis; and  
4

5 Whereas, obesity significantly increases the risk of developing these chronic conditions, leading  
6 to substantial morbidity, mortality, and healthcare costs across the United States; and  
7

8 Whereas, the AMA is committed to advancing evidence-based approaches to prevent and  
9 manage obesity-related chronic diseases, improve patient outcomes, and enhance healthcare  
10 delivery systems; and  
11

12 Whereas, regular monitoring of epidemiological trends, development of effective disease  
13 progression algorithms, and coordination of efforts to improve access to care are essential  
14 components of addressing the multifaceted challenges posed by obesity-related chronic  
15 diseases; therefore be it  
16

17 RESOLVED, that our American Medical Association convene an annual meeting of its  
18 Federation partners to comprehensively review the impact of obesity on hypertension,  
19 cardiovascular disease, type 2 diabetes, metabolic dysfunction-associated hepatitis (MASH)  
20 and other related comorbidities with a focus on monitoring epidemiology, developing algorithms  
21 to combat disease progression, and coordinating efforts to improve access to care (Directive to  
22 Take Action); and be it further  
23

24 RESOLVED, that our AMA shall feature presentations, workshops, and panel discussions  
25 covering the latest research findings, clinical guidelines, and best practices related to the  
26 prevention, diagnosis, and management of obesity-related chronic diseases (Directive to Take  
27 Action); and be it further  
28

29 RESOLVED, that our AMA shall invite renowned experts, researchers, clinicians, policymakers,  
30 and patient advocates to contribute their insights, experiences, and recommendations during  
31 the annual meeting (Directive to Take Action); and be it further  
32

33 RESOLVED, that our AMA shall collaborate with relevant stakeholders, including government  
34 agencies, healthcare systems, insurers, community organizations, and industry partners, to  
35 develop and implement strategies for combating obesity-related chronic diseases (Directive to  
36 Take Action); and be it further

- 1 RESOLVED, that our AMA assist in the discussion of epidemiological trends, development of  
2 evidence-based algorithms for disease management, and coordination of efforts to improve  
3 access to care for patients affected by obesity-related chronic diseases (Directive to Take  
4 Action); and be it further  
5  
6 RESOLVED, that our AMA shall publish a comprehensive report summarizing the discussions,  
7 findings, and recommendations from each annual meeting and disseminate it to member  
8 organizations, policymakers, healthcare providers, and the public (Directive to Take Action); and  
9 be it further  
10  
11 RESOLVED, that the AMA shall convene the first annual meeting in 2025 and subsequent  
12 meetings annually thereafter. (Directive to Take Action)

Fiscal Note: To Be Determined

Received: 4/30/2024

#### REFERENCES

1. Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, Paik J. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. *Clin Gastroenterol Hepatol*. 2024 Mar 21:S1542-3565(24)00287-8. doi: 10.1016/j.cgh.2024.03.006. Epub ahead of print. PMID: 38521116.
2. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge MP; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation*. 2021 May 25;143(21):e984-e1010. doi: 10.1161/CIR.0000000000000973. Epub 2021 Apr 22. PMID: 33882682; PMCID: PMC8493650.
3. Yanovski SZ, Yanovski JA. Approach to Obesity Treatment in Primary Care: A Review. *JAMA Intern Med*. Published online March 11, 2024. doi:10.1001/jamainternmed.2023.8526
4. Almuwaqqat Z, Hui Q, Liu C, et al. Long-Term Body Mass Index Variability and Adverse Cardiovascular Outcomes. *JAMA Netw Open*. 2024;7(3):e243062. doi:10.1001/jamanetworkopen.2024.3062

#### RELEVANT AMA POLICY

##### **Recognition of Obesity as a Disease H-440.842**

Our American Medical Association recognizes obesity as a disease state with multiple pathophysiological aspects requiring a range of interventions to advance obesity treatment and prevention.

Res. 420, A-13 Reaffirmed: CSAPH Rep. 08, A-23